CEPI Animation

Below you can see the prize winning animation developed for the CEPI launch campaign in January 2017. The #OutsmartEpidemics campaign was crowned winner of the Best of Use of Digital and STEM Campaign categories in the Chartered Institute of Public Relations (CIPR) Excellence Awards 2017.

Press releases

CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine

CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which Profectus and Emergent will receive up to $25 million to advance the development and manufacture of a vaccine against the Nipah virus, a bat-borne virus that can spread to both humans and livestock.

Read more here.

Strong Clinical Research Capacity in At-Risk Countries Key to Global Epidemic Prevention

New report outlines urgent need and opportunities in low- and middle-income countries where disease outbreaks most often strike

Read more here

CEPI Partners with the International AIDS Vaccine Initiative to Advance Lassa Fever Vaccine Development

Organizations aim to tackle WHO priority disease and to stockpile emergency vaccines

Read more here

Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS

Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases

Read more here  

Ethiopia joins CEPI, the gobal coalition fighting epidemics

As the first African country to partner with CEPI, Ethiopia helps fill a critical gap in the fight against the next Ebola or Zika

Media Release, Addis Ababa, Ethiopia, March 9, 2018 Coalition for Epidemic Preparedness Innovations

Read more here 

CEPI Partners with Themis Bioscience

Today Themis Bioscience and CEPI announce a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS.

Media release, Vienna, Austria and Oslo, Norway, March 7, 2018

Read more here.

CEPI announces new permanent board

Today, CEPI, the coalition launched one year ago to finance and coordinate the development of new vaccines to prevent and contain epidemics, announces the establishment of its new permanent Board.

Media release, 24 January 2018, London - Coalition for Epidemic Preparedness Innovations

Read more here

CfP to reduce time to develop vaccines against epidemics

Coalition aims to provide a global defence against emerging infectious diseases by developing platforms for rapid development and manufacturing of vaccines.

Media release, 5 September 2017, Oslo – Coalition for Epidemic Preparedness Innovations

Read more here.

Norway strengthens its commitment to CEPI

CEPI welcomes global leadership shown by government of Norway

Media release, Oslo 08 July 2017 – Coalition for Epidemic Preparedness Innovations

Read more here.

CEPI permanent CEO

Dr Richard Hatchett offered position as permanent CEO of CEPI

Media release, Oslo 28 Feb 2017 – Coalition for Epidemic Preparedness Innovations

Read more here.

CEPI officially launched

Global partnership launched to prevent epidemics with new vaccines

Media release, Davos 18 Jan 2017 – Coalition for Epidemic Preparedness Innovations

Read more here.

CEPI vaccine R&D pipeline and cost tracking survey

CEPI is inviting you to participate in a survey that is mapping vaccine research and development pipelines and associated costs for emerging infectious diseases.

To achieve its strategic objectives, and to make efficient use of its financial resources, CEPI needs to draw on a variety of vaccine candidates and leverage diversity of product development partners. CEPI is currently building up a comprehensive knowledge base on available vaccine candidates and their current status, in order to serve vaccine preparedness needs against non-commercial epidemic disease threats.

Our request

Through this survey, you are asked to:

  • Report the current status of development of vaccine candidates against non-commercial epidemic disease threats.
  • Clarify current sources of funding, development costs incurred and future funding needs for bringing the vaccines through phase II and potentially phase III in response to potential disease outbreaks.
  • Specify main drivers of R&D costs and technical success to date and identify potential drivers of future costs and technical risks for bringing your vaccine candidates through late stages of clinical development.

Diseases in scope

  • Diseases that are of main interest to CEPI include those listed by the WHO Blueprint as priority diseases: Crimean Congo haemorrhagic fever, Lassa fever, MERS-CoV, Severe acute respiratory syndrome, Nipah, Rift Valley Fever, Chikungunya, Zika, Severe fever with thrombocytopaenia syndrome, Ebola, Marburg. (For more details, see here).
  • Other diseases that have epidemic potential and which are not included in the WHO priority list.


Please submit your completed survey file via our webform or email.

CEPI vaccine R&D pipeline and cost tracking survey

Please note that you will have to click "enable content" before you can edit the text.



CEPI Newsletter

CEPI Newsletter 17 April 2018



CEPI Newsletter 12 February 2018



CEPI Newsletter 19 January 2018



CEPI Newsletters 2017



CEPI Newsletters 2016